> ## Content Index
> Fetch the complete content index at: https://www.techloy.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# INFOGRAPHIC: Top Asian Startup Funding — Week 3, 2025
- URL: https://www.techloy.com/infographic-top-asian-startup-funding-week-3-2025/
- Published: 2025-01-17T09:41:23.000Z
- Updated: 2025-01-17T09:41:23.000Z
- Description: These are the funding deals we tracked in the Asian region this week – featuring Mirxes, Ecozen, Sarla Aviation, Skor Technologies, and MetAI.
- Author: Kelechi Edeh
- Tags: / Startups, Tech in Asia, / Money

- Singapore-based biotech and cancer diagnostics firm **Mirxes** secured $40 million to expand its miRNA technology platform for early-stage cancer detection across Asia-Pacific.
- **Ecozen**, a Pune-based climate tech startup, raised $23 million in debt to scale its solar-powered energy storage and climate-smart deeptech solutions.
- **Sarla Aviation** obtained $10 million in Series A1 funding to accelerate the development of its flying taxi prototype and launch an air ambulance service in India.
- Indonesia's **Skor Technologies** secured $6.2 million in pre-Series A funding to expand its Skorcard digital-first credit card and tackle Indonesia's underpenetrated consumer credit market.
- Taiwan-based **MetAI** raised $4 million in a seed round backed by Nvidia to develop AI-powered digital twins for robotics and industrial automation.

---

## Mirxes Secures $40 Million to Expand Cancer Detection Across Asia

Singapore-based Mirxes, a pioneer in cancer diagnostics, has raised $40 million in funding from CBC Group's R-Bridge Healthcare Fund.

Mirxes specializes in miRNA-based cancer detection and is known for GASTROClear, the first regulatory-approved blood test for gastric cancer. The company aims to expand its cancer screening solutions to include lung, liver, and colorectal cancer detection in high-growth regions across Asia-Pacific.

With this investment, Mirxes will enhance its miRNA technology platform, strengthen its commercial presence across Asia, and drive further research into early-stage cancer diagnostics. As cancer rates rise, particularly in aging populations, Mirxes is positioning itself as a leader in next-generation liquid biopsy solutions.

![](https://storage.ghost.io/c/c1/a6/c1a6d111-d951-41ad-a392-c1e841210b93/content/images/2025/01/INFOGRAPHIC---Top-Asian-Startup-Funding---Week-3--2025.png)